Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.78 |
| ▸ | HPGD | P15428 | 7/20 | 0.78 |
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.78 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.78 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.61 |
| ▸ | MEN1 | O00255 | 3/20 | 0.61 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.61 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.61 |
| ▸ | HTT | P42858 | 1/20 | 0.61 |
| ▸ | POLB | P06746 | 1/20 | 0.61 |
| ▸ | GAA | P10253 | 1/20 | 0.61 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.61 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.61 |
| ▸ | EGFR | P00533 | 1/20 | 0.59 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.57 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.56 |
| ▸ | MAPT | P10636 | 2/20 | 0.55 |
| ▸ | TSHR | P16473 | 1/20 | 0.54 |
| ▸ | GFER | P55789 | 1/20 | 0.54 |
| ▸ | GSK3A | P49840 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30283788 | 0.88 | KDM4E (1.00) | ALDH1A1HPGDKDM4ESMN1; SMN2KMT2A | |
| SCHEMBL2798115 | 0.88 | KDM4E (1.00) | ALDH1A1HPGDKDM4ESMN1; SMN2KMT2A | |
| SCHEMBL16814399 | 0.86 | ALDH1A1 (0.63) | ALDH1A1HPGDKDM4ESMN1; SMN2KMT2A | |
| SCHEMBL31677372 | 0.83 | KDM4E (0.71) | ALDH1A1HPGDKDM4ESMN1; SMN2KMT2A | |
| SCHEMBL8986966 | 0.83 | KDM4E (0.71) | ALDH1A1HPGDKDM4ESMN1; SMN2KMT2A | |
| SCHEMBL30175823 | 0.81 | MEN1 (0.69) | ALDH1A1HPGDKDM4ESMN1; SMN2KMT2A | |
| SCHEMBL8987324 | 0.81 | HPGD (0.68) | ALDH1A1HPGDKDM4ESMN1; SMN2KMT2A | |
| SCHEMBL8987344 | 0.80 | HPGD (0.67) | ALDH1A1HPGDKDM4ESMN1; SMN2KMT2A | |
| SCHEMBL28133664 | 0.80 | HPGD (0.67) | ALDH1A1HPGDKDM4ESMN1; SMN2KMT2A | |
| SCHEMBL31253416 | 0.79 | SMN1; SMN2 (0.56) | ALDH1A1HPGDKDM4ESMN1; SMN2KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115209883-B | Novel cell metabolism regulating compound and use thereof | 新月生物科学 | 2025-05-20 | — | — | CN | disclosed |
| US-20230183179-A1 | NOVEL CELL METABOLISM MODULATING COMPOUNDS AND USES THEREOF | CRESCENTA BIOSCIENCES (US) | 2023-06-15 | — | — | US | disclosed |
| US-20230183179-A1 | NOVEL CELL METABOLISM MODULATING COMPOUNDS AND USES THEREOF | CRESCENTA BIOSCIENCES (US) | 2023-06-15 | — | — | US | disclosed |
| US-20230183179-A1 | NOVEL CELL METABOLISM MODULATING COMPOUNDS AND USES THEREOF | CRESCENTA BIOSCIENCES (US) | 2023-06-15 | — | — | US | disclosed |
| EP-4093384-A1 | NOVEL CELL METABOLISM MODULATING COMPOUNDS AND USES THEREOF | Crescenta Biosciences (US) | 2022-11-30 | — | — | EP | disclosed |
| CN-115209883-A | Novel cell metabolism-regulating compounds and uses thereof | 新月生物科学 | 2022-10-18 | — | — | CN | disclosed |
| WO-2021150645-A1 | NOVEL CELL METABOLISM MODULATING COMPOUNDS AND USES THEREOF | CRESCENTA BIOSCIENCES (US) | 2021-07-29 | — | — | WO | disclosed |
| WO-2021150645-A1 | NOVEL CELL METABOLISM MODULATING COMPOUNDS AND USES THEREOF | CRESCENTA BIOSCIENCES (US) | 2021-07-29 | — | — | WO | disclosed |
| US-6358973-B1 | FOR THERAPY OF ALLERGIC OR INFLAMMATORY DISEASE | ZAMBON GROUP S.P.A. (IT) | 2002-03-19 | — | — | US | disclosed |
| EP-1121353-A1 | BENZAZINE DERIVATIVES AS PHOSPHODIESTERASE 4 INHIBITORS | ZAMBON GROUP S.p.A. (IT) | 2001-08-08 | — | — | EP | disclosed |
| WO-2000021947-A1 | BENZAZINE DERIVATIVES AS PHOSPHODIESTERASE 4 INHIBITORS | ZAMBON GROUP S.P.A. (IT) | 2000-04-20 | — | — | WO | disclosed |
| US-5492915-A | ANTIINFLAMMATORY AGENTS | RHONE-POULENC RORER S.A. (FR) | 1996-02-20 | — | — | US | disclosed |
| US-5366982-A | Antiinflammatory agents or antihistamines | RHONE-POULENC RORER S.A. (FR) | 1994-11-22 | — | — | US | disclosed |
| EP-0540604-A1 | SUBSTITUTED BICYCLIC BIS-ARYL COMPOUNDS EXHIBITING SELECTIVE LEUKOTRIENE B 4? ANTAGONIST ACTIVITY, THEIR PREPARATION AND USE IN PHARMACEUTICAL COMPOSITIONS | Aventis Pharma S.A. (FR) | 1993-05-12 | — | — | EP | disclosed |
| WO-1992001675-A2 | SUBSTITUTED BICYCLIC BIS-ARYL COMPOUNDS EXHIBITING SELECTIVE LEUKOTRIENE B4 ANTAGONIST ACTIVITY, THEIR PREPARATION AND USE IN PHARMACEUTICAL COMPOSITIONS | RHONE-POULENC RORER S.A. (FR) | 1992-02-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230183179-A1 | NOVEL CELL METABOLISM MODULATING COMPOUNDS AND USES THEREOF | FABP4, FABP1, FABP3 | ALDH1A1 868/4885HPGD 1825/4885KDM4E 2557/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.